

Curriculum Vitae

*CV must be written in English

Personal Information



Title (i.e. Prof., Dr., etc.)	Prof.
Name (First / Middle / Last)	Rupert Leong
Degree (i.e. MD, MSc, PhD, etc.)	MBBS, FRACP, MD, AGAF, FGESA
Country	Australia
Affiliation	University of Sydney

Educational Background

1994 MBBS Bachelor of Medicine, Bachelor of Surgery (University of Western Australia)
2000 FRACP Gastroenterology and Hepatology Fellowship of the Royal Australasian College of Physicians
2004 MD Doctor of Medicine (Chinese University of Hong Kong)
2012 AGAF Fellowship of the American Gastroenterological Association
2025 FGESA Fellowship of the Gastroenterological Society of Australia

Professional Experience

2015 – present Professor of Medicine, University of Sydney
2015 – present Professor of Medicine, Macquarie University
2007 – present Director of Endoscopy, Head of IBD Services, Concord Hospital, Sydney, Australia

Professional Organizations

2026 – present Member, ECCO Global Task Force (Australasia)
2025 – present Member, IOIBD
2025 – present Trustee, Journal of Gastroenterology and Hepatology Foundation
2024 – present Delegate, ECCO Consensus for Ulcerative Colitis
2022 – present Associate Editor, Therapeutic Advances in Gastroenterology
2012 – present Director of IBD Sydney
2016 - present Director of IBD School

Main Scientific Publications

1. Caron B, Jairath V, Sands BE, Rubin DT, Allocca M, Laurent V, Novak K, Panaccione R, Bossuyt P, Bruining DH, Dignass A, Dotan I, Fletcher J, Fumery M, Furfaro F, Halfvarson J, Hart A, Kobayashi T, Cleveland NK, Kucharzik T, Laghi A, Lakatos PL, Leong RW, Loftus EV Jr, Louis E, Magro F, Olivera PA, Shaji S, Siegmund B, Vavricka SR, Danese S, Stoker J, Peyrin-Biroulet L. International Magnetic Resonance Imaging Consensus for use in Luminal Crohn's Disease Trials and Clinical Practice. *Clin Gastroenterol Hepatol*. 2026 Apr;24(4):1130-1140. doi: 10.1016/j.cgh.2025.08.019. Epub ahead of print. PMID: 40882718.

2. Vieujean S, Atreya R, Buda A, Caradec J, Citi S, Danese S, Dewit O, Friedrich M, Ghosh S, Iacucci M, Jairath V, Kaser A, Leong RW, Neurath MF, Pierre N, Pohin M, Rath T, Rivière P, Travis S, Westcott J, Zeissig S, Peyrin-Biroulet L. Tools and Advanced Imaging Technologies for Assessing Intestinal Epithelial Barrier Integrity: A Systematic Review. *Am J Physiol Gastrointest Liver Physiol*. 2026 Feb 12. doi: 10.1152/ajpgi.00447.2025. Epub ahead of print. PMID: 41677575.
3. Schreiber S, Danese S, Vermeire S, Leong RW, Pradhan V, Singh RSP, Yu D, Messing D, Neubert H, Palandra J, Tehlirian C, Gale JD. Efficacy and safety of the interleukin-10-fragment F8 fusion protein PF-06687234 as add-on therapy to infliximab in patients with active ulcerative colitis: a randomized, phase IIa clinical trial. *Ther Adv Gastroenterol*. 2026 Feb 10;19:17562848251410784. doi: 10.1177/17562848251410784. PMID: 41684726; PMCID: PMC12891412.
4. Pudipeddi A, Chaemsupaphan T, Arzivian A, Kim YS, Paramsothy S, Kariyawasam V, Leong RW. Vedolizumab in inflammatory bowel disease: pharmacokinetics and the role of immunomodulator co-therapy. *Ther Adv Gastroenterol*. 2026 Jan 19;19:17562848251414825. doi: 10.1177/17562848251414825. PMID: 41568061; PMCID: PMC12816544.
5. Li Wai Suen CFD, Choy MC, Con D, Cheng K, Nigro J, Breheney K, Boyd K, Pena R, Burrell K, Rosella O, Proud D, Brouwer R, Gorelik A, Liew D, Connell W, Wright EK, Taylor K, Pudipeddi A, Sawers M, Christensen B, Ng W, Begun J, Radford-Smith GL, Garg M, Martin N, van Langenberg DR, Ding NS, Beswick L, Leong RW, Sparrow MP, Grosserichter-Wagener C, Velthuis HT, Visvanathan K, De Cruz P. Early Infliximab Levels and Clearance Predict Outcomes After Infliximab Rescue in Acute Severe Ulcerative Colitis: Results From PREDICT-UC. *Gastroenterology*. 2026 Jan;170(1):118-131. doi: 10.1053/j.gastro.2025.07.020. Epub ahead of print. PMID: 40701396.
6. Raich SS, Majzoub ME, Haifer C, Paramsothy S, Shamim MMI, Borody TJ, Leong RW, Kaakoush NO. Bacterial taxonomic and functional changes following oral lyophilized donor fecal microbiota transplantation in patients with ulcerative colitis. *mSystems*. 2025 Oct 22;10(10):e0099125. doi: 10.1128/msystems.00991-25. Epub 2025 Sep 15. PMID: 40952001; PMCID: PMC12542657.
7. An YK, Lindsay N, Allan N, Khoo E, Fernandes R, Gilmore R, Amiss A, Pham H, Ooi SY, Thin L, Lightowler D, Connor SJ, Williams A, De Cruz P, Li Wai Suen CFD, Kariyawasam V, Mitrev N, Ghaly S, Andrews JM, Christensen B, Sparrow MP, White LS, Bryant R, Ding NS, Leong RW, Van Langenberg DR, Selteneich H, Subramaniam K, Radford-Smith G, Begun J. Australian Real-World Effectiveness and Safety of Ustekinumab for the Treatment of Crohn's Disease: Results of the AURORA Study, Including the ANZIBD Consortium. *JGH Open*. 2025 Dec 9;9(12):e70322. doi: 10.1002/jgh3.70322. PMID: 41384275; PMCID: PMC12689938.
8. Liu CS, Merrick B, Taboun ZS, Mullish BH, Goldenberg SD, Terveer EM, Porcari S, Bradbury RS, Ianiro G, Ng SC; Donor Screening Working Group; Kao D, Kuijper E. Towards optimising and standardising donor screening for faecal microbiota transplantation. *Gut*. 2025 Dec 4;gutjnl-2025-336532. doi: 10.1136/gutjnl-2025-336532. Epub ahead of print. PMID: 41298101.

AOCC 2026

IMKASID 2026

JUNE 25 (Thu.) - 27 (Sat.), 2026 | COEX, SEOUL, KOREA



-
9. Arzivian A, Rubin DT, Seow CH, Kerkham A, Tran Y, Leong RW. The Risk of Relapse Associated With Discontinuation of 5-Aminosalicylates in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. *Inflamm Bowel Dis*. 2025 Dec 3;:izaf277. doi: 10.1093/ibd/izaf277. Epub ahead of print. PMID: 41338243.
-
10. Samnani S, Ray CM, Gill P, Stein L, Buhler KA, Leong RW, Smith RL, De Cruz P, Kaplan GG, Seow CH, Lu C, Guizzetti L, Hoentjen F, Marshall JK, Singh S, Panaccione R, Novak KL, Ma C. Diagnostic Accuracy of Noninvasive Biomarkers and Imaging for Evaluating Postoperative Recurrence in Crohn's Disease. *Clin Gastroenterol Hepatol*. 2025 Dec;23(13):2433-2447.e9. doi: 10.1016/j.cgh.2025.03.030. Epub 2025 Jun 2. PMID: 40467019; PMCID: PMC12354279.
-
11. Law CCY, Sheskier R, Viera-Feliciano N, Delgado-Nieves A, Seth S, Hanžel J, Ma C, Colombel JF, Levine AC, Spencer EA; CORE-IBD Collaborators. Evaluation and Management of Glucocorticoid-Induced Adrenal Insufficiency in IBD: An Expert Opinion. *Inflamm Bowel Dis*. 2025 Nov 1;31(11):3077-3092. doi: 10.1093/ibd/izaf136. PMID: 40587340.
-
12. Hanžel J, Solitano V, Vuyyuru SK, Panaccione R, Sands BE, Peyrin-Biroulet L, Danese S, D'Haens GR, Atreya R, Allez M, Bernstein CN, Bossuyt P, Bressler B, Bryant RV, Cohen BL, Colombel JF, D'Amico F, Dignass A, Dubinsky M, Fleshner P, Geary RB, Hanauer SB, Hart AL, Kayal M, Kucharzik T, Lakatos PL, Louis E, Magro F, Narula N, Leong RW, Panés J, Raine T, Ran Z, Regueiro MD, Reinisch W, Singh S, Steinhart AH, Travis S, Ungaro RC, van der Woude CJ, Yamamoto T, Ahuja V, Rubin DT, Dulai PS, Cornfield LJ, Hogan M, Sandborn WJ, Feagan BG, Jairath V, Ma C. An International Consensus on Appropriate Management of Corticosteroids in Clinical Trials in Inflammatory Bowel Disease. *Gastroenterology*. 2025 Nov;169(6):1282-1293. doi: 10.1053/j.gastro.2025.05.015. Epub 2025 May 28. PMID: 40446946; PMCID: PMC12354294.
-